This may in part be due to a positive perception of the relative ease of weight loss with the medication. However, it additionally raises the possibility of a direct brain effect of GLP-1 receptor agonists that could target mental disorders common in obesity and T2D. The gene discussed is GLP1R; the disease is obesity disorder.